14

result(s)

Word(s)
Publication type
Policy area
Keyword
Date

Covid-19 Newsletter 2: Exit strategy

03-07-2020

As EU Member States embark on a cautious de-confinement path, the economy slides into recession and the question of the proportionality of public health-related measures and their economic consequences is increasingly present in the public debate. As long as a vaccine (or an effective treatment) for the Covid-19 disease is not found and deployed, post-Covid-19 societies will have to coexist with the virus, and find an equilibrium between the social constraints resulting from health protecting measures ...

As EU Member States embark on a cautious de-confinement path, the economy slides into recession and the question of the proportionality of public health-related measures and their economic consequences is increasingly present in the public debate. As long as a vaccine (or an effective treatment) for the Covid-19 disease is not found and deployed, post-Covid-19 societies will have to coexist with the virus, and find an equilibrium between the social constraints resulting from health protecting measures and the need to mitigate as much as possible a huge economic shock, which if not addressed adequately, could have unpredictable social and political consequences. The Covid-19 crisis has shown above all the importance of joint European action. Although public health is primarily the competence of the Member States, the European Parliament has called on the Commission and the Member States to act together and to rise to the challenge and ensure that the Union emerges stronger from this crisis. In particular, a differentiated but coordinated post-lockdown approach in the EU should be ensured, in order to avoid a resurgence of the virus. The present Covid-19 Newsletter focuses on the de-confinement strategies and EU measures to support the economic recovery. An update of ongoing Covid-19 related expertise work for the ECON, EMPL, ENVI, ITRE and IMCO committees is provided at the end of this document.

Medicine shortage in the EU during the novel coronavirus outbreak

15-05-2020

The novel coronavirus outbreak is an unprecedented public health crisis with far-reaching consequences. It has highlighted the EU’s long-existing structural problems related to the supply of medicines, and the dependency on third-country import for certain essential and critical medicines and ingredients. While public health policy, including the organisation of the delivery of healthcare and the sales of medicines remains in the competence of the Member States, it has also become clear that cooperation ...

The novel coronavirus outbreak is an unprecedented public health crisis with far-reaching consequences. It has highlighted the EU’s long-existing structural problems related to the supply of medicines, and the dependency on third-country import for certain essential and critical medicines and ingredients. While public health policy, including the organisation of the delivery of healthcare and the sales of medicines remains in the competence of the Member States, it has also become clear that cooperation with the pharmaceutical industry, amongst the Member States, and with the Commission and the Europan Medicines Agency, is key in resolving the problems of medicine shortages in these extraordinary times This paper looks into the causes of medicine shortage during the novel coronavirus pandemic in the Union, and the responses and solutions at European level.

Novel Coronavirus Outbreak - State of Play, and the EU’s Public Health Response

07-04-2020

The novel coronavirus pandemic spreads globally, and the whole world, including the countries of the European Union are facing a serious public health, economic and financial, and social crises. This paper takes stock of how the pandemic evolved, and what response action the Union has taken and prepares to take, in the field of public health. It follows up on the briefing which was published in February 2020.

The novel coronavirus pandemic spreads globally, and the whole world, including the countries of the European Union are facing a serious public health, economic and financial, and social crises. This paper takes stock of how the pandemic evolved, and what response action the Union has taken and prepares to take, in the field of public health. It follows up on the briefing which was published in February 2020.

Workshop proceedings "Cancer prevention-modifiable risk factors"

16-03-2020

On 18 February 2020, the Health Working Group of the Committee on Environment, Public Health and Food Safety (ENVI) held a workshop on cancer prevention, focussing on modifiable risk factors. Dolores Montserrat and Sara Cerdas MEPs, the Co-Chairs of the Health Working Group, presided over the meeting. This briefing summarises the presentations that were delivered by the invited experts.

On 18 February 2020, the Health Working Group of the Committee on Environment, Public Health and Food Safety (ENVI) held a workshop on cancer prevention, focussing on modifiable risk factors. Dolores Montserrat and Sara Cerdas MEPs, the Co-Chairs of the Health Working Group, presided over the meeting. This briefing summarises the presentations that were delivered by the invited experts.

Novel Coronavirus Outbreak - State of play with the epidemics; preparedness and response measurers

17-02-2020

Following the extraordinary Council meeting of health ministers on 13 February 2020, this paper summarises the latest available information on the novel coronavirus outbreak, and the Union’s preparedness and response actions. It is an extended and updated version of the “At a Glance” overview, published on 14 February 2020.

Following the extraordinary Council meeting of health ministers on 13 February 2020, this paper summarises the latest available information on the novel coronavirus outbreak, and the Union’s preparedness and response actions. It is an extended and updated version of the “At a Glance” overview, published on 14 February 2020.

Novel Coronavirus Outbreak

13-02-2020

The paper summarises the latest available information on the novel coronavirus outbreak, and the Union’s preparedness and response actions .

The paper summarises the latest available information on the novel coronavirus outbreak, and the Union’s preparedness and response actions .

Commitments made at the hearing of Virginijus SINKEVIČIUS, Commissioner-designate - Environment, Oceans and Fisheries

22-11-2019

The commissioner-designate, Virginijus Sinkevičius, appeared before the European Parliament on 3 October 2019 to answer questions put by MEPs from the Committees on ENVI and PECH. During the hearing, he made a number of commitments which are highlighted in this document. These commitments refer to his portfolio, as described in the mission letter sent to him by Ursula von der Leyen, President-elect of the European Commission, including conserving Europe’s natural environment and prosperous and sustainable ...

The commissioner-designate, Virginijus Sinkevičius, appeared before the European Parliament on 3 October 2019 to answer questions put by MEPs from the Committees on ENVI and PECH. During the hearing, he made a number of commitments which are highlighted in this document. These commitments refer to his portfolio, as described in the mission letter sent to him by Ursula von der Leyen, President-elect of the European Commission, including conserving Europe’s natural environment and prosperous and sustainable fishing and a thriving blue economy.

Commitments made at the hearing of Frans TIMMERMANS, Executive Vice-President-designate - European Green Deal

22-11-2019

The commissioner-designate, Frans Timmermans, appeared before the European Parliament on 08 October 2019 to answer questions from MEPs in the Committee on the Environment, Public Health and Food Safety. During the hearing, he made a number of commitments which are highlighted in this document. These commitments refer to his portfolio, as described in the mission letter sent to him by Ursula von der Leyen, President-elect of the European Commission, including "A European Green Deal" and a "Climate ...

The commissioner-designate, Frans Timmermans, appeared before the European Parliament on 08 October 2019 to answer questions from MEPs in the Committee on the Environment, Public Health and Food Safety. During the hearing, he made a number of commitments which are highlighted in this document. These commitments refer to his portfolio, as described in the mission letter sent to him by Ursula von der Leyen, President-elect of the European Commission, including "A European Green Deal" and a "Climate Action". The quotes included in this document only make reference to the oral commitments made during the hearing.

Public health

01-02-2018

The Treaty of Lisbon has enhanced the importance of health policy, stipulating that ‘a high level of human health protection shall be ensured in the definition and implementation of all Community policies and activities’. Primary responsibility for health protection and, in particular, healthcare systems continues to lie with the Member States. However, the EU has an important role to play in improving public health, preventing and managing diseases, mitigating sources of danger to human health, ...

The Treaty of Lisbon has enhanced the importance of health policy, stipulating that ‘a high level of human health protection shall be ensured in the definition and implementation of all Community policies and activities’. Primary responsibility for health protection and, in particular, healthcare systems continues to lie with the Member States. However, the EU has an important role to play in improving public health, preventing and managing diseases, mitigating sources of danger to human health, and harmonising health strategies between Member States. The EU has successfully implemented a comprehensive policy, through the ‘Health for Growth’ health strategy and its action programme (2014-2020) and a body of secondary legislation. The European Social Fund Plus (ESF+) will continue to provide funding during the 2021-2027 programming period.

Medicines and Medical Devices

01-02-2018

Medicines and medical devices are subject to the rules of the single market and have a direct impact on people’s health. A robust legal framework is in place to protect public health and guarantee the safety of these products. It covers the full cycle, from trials and testing, to authorisation for placement on the market, to surveillance and recall. Access to affordable medicines, the fight against antimicrobial resistance, the ethical conduct of clinical trials, and incentives to research and development ...

Medicines and medical devices are subject to the rules of the single market and have a direct impact on people’s health. A robust legal framework is in place to protect public health and guarantee the safety of these products. It covers the full cycle, from trials and testing, to authorisation for placement on the market, to surveillance and recall. Access to affordable medicines, the fight against antimicrobial resistance, the ethical conduct of clinical trials, and incentives to research and development are just some of the key issues the EU deals with in this field. In order to keep up with scientific and technological advancement and respond to emerging health threats, legislative and policy measures are subject to regular evaluation and follow-up.